Is There any Relationship Between the Repeated Complications of Sickle Cell Disease and the Potential Development of Acute Leukemia?
Giovanna CannasMohamed ElhamriXavier ThomasPublished in: Oncology and therapy (2024)
Sickle cell disease (SCD) is a severe monogenic hereditary hemoglobinopathy that is characterized by repeated clinical and biological manifestations able to generate stress erythopoiesis. A clonal hematopoiesis involving mainly variants of TP53, DNMT3A, ASXL1, and/or TET2 may be more prevalent in patients with SCD, suggesting that mutations in these genes may lead to an increased risk of leukemia. An increased prevalence of leukemia in patients with SCD has been confirmed by an increasing number of acute myeloid leukemia cases with myelodysplastic features reported in this patient population even in the absence of disease-modifying treatments. This leads to the hypothesis of a mechanism involving multifactorial causes through the pathophysiologic manifestations of SCD, in which cells are undergoing constant hematopoietic hyperplasia, inducing genomic damage and somatic mutations.
Keyphrases
- sickle cell disease
- acute myeloid leukemia
- bone marrow
- copy number
- allogeneic hematopoietic stem cell transplantation
- induced apoptosis
- risk factors
- dna methylation
- genome wide
- oxidative stress
- cell cycle arrest
- endoplasmic reticulum stress
- cell proliferation
- drug induced
- climate change
- genome wide identification
- genome wide analysis